Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Merck
McKinsey
AstraZeneca
Harvard Business School

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,513,262

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 8,513,262 protect, and when does it expire?

Patent 8,513,262 protects TYKERB and is included in one NDA.

This patent has seventy-nine patent family members in forty-six countries.

Summary for Patent: 8,513,262
Title:Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
Abstract: A process for the preparation of a compound of formula (I) ##STR00001## comprising the steps: (a) reacting a compound of formula (II) ##STR00002## wherein L and L' are suitable leaving groups, with a compound of formula (III) UNH.sub.2 (III) to prepare a compound of formula (IV) ##STR00003## and subsequently (b) substituting the group R.sup.1 by replacement of the leaving group L'.
Inventor(s): Carter; Malcolm Clive (Ware, GB), Cockerill; George Stuart (Bedford, GB), Lackey; Karen Elizabeth (Hillsborough, NC)
Assignee: GlaxoSmithKline LLC (Philadelphia, PA)
Application Number:12/691,784
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form;

Drugs Protected by US Patent 8,513,262

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis TYKERB lapatinib ditosylate TABLET;ORAL 022059-001 Mar 13, 2007 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,513,262

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9800569Jan 12, 1998
99/00048Jan 08, 1999

International Family Members for US Patent 8,513,262

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1446   Start Trial
Argentina 015507   Start Trial
Argentina 066982   Start Trial
Austria 270670   Start Trial
Austria 322491   Start Trial
Austria 417847   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
McKinsey
Colorcon
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.